Cyclosporine A affects the in vitro expression of T cell activation-related molecules and cytokines in dogs

Veterinary Immunology and Immunopathology

Volumn 140, Issue 3-4, 2011, Pages 175-180

  Fellman, C L ^a   Stokes, J V ^a   Archer, T M ^a   Pinchuk, L M ^a   Lunsford, K V ^a   Mackin, A J ^a  

^a MISSISSIPPI STATE UNIVERSITY   (United States)

Author keywords

Cyclosporine; Cytokine; Dog; Interleukin 2; Lymphocyte; Pharmacodynamics

Indexed keywords

BIOLOGICAL MARKER; CYCLOSPORIN A; FAS ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL ASSAY; CELL ISOLATION; CELL SURFACE; CONTROLLED STUDY; CYTOKINE RELEASE; DOG; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; FLOW CYTOMETRY; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIGENS, CD95; BIOLOGICAL MARKERS; CYCLOSPORINE; CYTOKINES; DOGS; FLOW CYTOMETRY; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-GAMMA; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; INTERLEUKIN-4; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES;

CANIS FAMILIARIS;

EID: 79952184882     PISSN: 01652427     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vetimm.2010.11.005     Document Type: Article

References (36)

1. Allenspach K., Rufenacht S., Sauter S., Grone A., Steffan J., Strehlau G., Gaschen F. Pharmacokinetics and clinical efficacy of cyclosporine treatment of dogs with steroid-refractory inflammatory bowel disease. J. Vet. Intern. Med. 2006, 20:239-244.
2. Andersson J., Nagy S., Groth C.G., Andersson U. Effects of FK506 and cyclosporin A on cytokine production studied in vitro at a single-cell level. Immunology 1992, 75:136-142.
3. Barten M.J., Dhein S., Chang H., Bittner H.B., Tarnok A., Rahmel A., Mohr F.W., Gummert J.F. Assessment of immunosuppressive drug interactions: inhibition of lymphocyte function in peripheral human blood. J. Immunol. Methods 2003, 283:99-114.
4. Barten M.J., Tarnok A., Garbade J., Bittner H.B., Dhein S., Mohr F.W., Gummert J.F. Pharmacodynamics of T-cell function for monitoring immunosuppression. Cell Prolif. 2007, 40:50-63.
5. Beagles K.E., Peterson L., Zhang X., Morris J., Kiem H.P. Cyclosporine inhibits the development of green fluorescent protein (GFP)-specific immune responses after transplantation of GFP-expressing hematopoietic repopulating cells in dogs. Hum. Gene Ther. 2005, 16:725-733.
6. Bohler T., Nolting J., Kamar N., Gurragchaa P., Reisener K., Glander P., Neumayer H.H., Budde K., Klupp J. Validation of immunological biomarkers for the pharmacodynamic monitoring of immunosuppressive drugs in humans. Ther. Drug Monit. 2007, 29:77-86.
7. Daigle J.C. More economical use of cyclosporine through combination drug therapy. J. Am. Anim. Hosp. Assoc. 2002, 38:205-208.
8. Flores M.G., Zhang S., Ha A., Holm B., Reitz B.A., Morris R.E., Borie D.C. In vitro evaluation of the effects of candidate immunosuppressive drugs: flow cytometry and quantitative real-time PCR as two independent and correlated read-outs. J. Immunol. Methods 2004, 289:123-135.
9. Gilger B.C., Andrews J., Wilkie D.A., Wyman M., Lairmore M.D. Cellular immunity in dogs with keratoconjunctivitis sicca before and after treatment with topical 2% cyclosporine. Vet. Immunol. Immunopathol. 1995, 49:199-208.
10. Grinyo J.M., Cruzado J.M., Millan O., Caldes A., Sabate I., Gil-Vernet S., Seron D., Brunet M., Campistol J.M., Torras J., Martorell J. Low-dose cyclosporine with mycophenolate mofetil induces similar calcineurin activity and cytokine inhibition as does standard-dose cyclosporine in stable renal allografts. Transplantation 2004, 78:1400-1403.
11. Guaguere E., Steffan J., Olivry T. Cyclosporin A: a new drug in the field of canine dermatology. Vet. Dermatol. 2004, 15:61-74.
12. Hardie R.J., Gregory S.P., Tomlin J., Sturgeon C., Lipscomb V., Ladlow J. Cyclosporine treatment of anal furunculosis in 26 dogs. J. Small Anim. Pract. 2005, 46:3-9.
13. Hartel C., Fricke L., Schumacher N., Kirchner H., Muller-Steinhardt M. Delayed cytokine mRNA expression kinetics after T-lymphocyte costimulation: a quantitative measure of the efficacy of cyclosporin A-based immunosuppression. Clin. Chem. 2002, 48:2225-2231.
14. Ho S., Clipstone N., Timmermann L., Northrop J., Graef I., Fiorentino D., Nourse J., Crabtree G.R. The mechanism of action of cyclosporin A and FK506. Clin. Immunol. Immunopathol. 1996, 80:S40-S45.
15. Kahan B.D., Keown P., Levy G.A., Johnston A. Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. Clin. Ther. 2002, 24:330-350. discussion 329.
16. Katayama M., Igarashi H., Fukai K., Tani K., Momota Y., Kamishina H., Tagawa M. Fluconazole decreases cyclosporine dosage in renal transplanted dogs. Res. Vet. Sci. 2010, 89:124-125.
17. Kobayashi T., Momoi Y., Iwasaki T. Cyclosporine A inhibits the mRNA expressions of IL-2, IL-4 and IFN-gamma, but not TNF-alpha, in canine mononuclear cells. J. Vet. Med. Sci. 2007, 69:887-892.
18. Letourneau S., Krieg C., Pantaleo G., Boyman O. IL-2- and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets. J. Allergy Clin. Immunol. 2009, 123:758-762.
19. Loken M.R., Brosnan J.M., Bach B.A., Ault K.A. Establishing optimal lymphocyte gates for immunophenotyping by flow cytometry. Cytometry 1990, 11:453-459.
20. Mathews K.A., Holmberg D.L. Kidney transplantation in dogs with naturally occurring end-stage renal disease. J. Am. Anim. Hosp. Assoc. 2000, 36:475.
21. Mathews K.A., Sukhiani H.R. Randomized controlled trial of cyclosporine for treatment of perianal fistulas in dogs. J. Am. Vet. Med. Assoc. 1997, 211:1249-1253.
22. Murphy K., Travers P., Walport M. Janeway's Immunobiology 2008, Garland Science, New York, NY. 7th edition.
23. Olivry T., Mueller R.S. Evidence-based veterinary dermatology: a systematic review of the pharmacotherapy of canine atopic dermatitis. Vet. Dermatol. 2003, 14:121-146.
24. Rao A., Luo C., Hogan P.G. Transcription factors of the NFAT family: regulation and function. Annu. Rev. Immunol. 1997, 15:707-747.
25. Robson D.C., Burton G.G. Cyclosporin: applications in small animal dermatology. Vet. Dermatol. 2003, 14:1-9.
26. Rovira P., Mascarell L., Truffa-Bachi P. The impact of immunosuppressive drugs on the analysis of T cell activation. Curr. Med. Chem. 2000, 7:673-692.
27. Stalder M., Birsan T., Holm B., Haririfar M., Scandling J., Morris R.E. Quantification of immunosuppression by flow cytometry in stable renal transplant recipients. Ther. Drug Monit. 2003, 25:22-27.
28. Steffan J., Favrot C., Mueller R. A systematic review and meta-analysis of the efficacy and safety of cyclosporin for the treatment of atopic dermatitis in dogs. Vet. Dermatol. 2006, 17:3-16.
29. Steffan J., Parks C., Seewald W. Clinical trial evaluating the efficacy and safety of cyclosporine in dogs with atopic dermatitis. J. Am. Vet. Med. Assoc. 2005, 226:1855-1863.
30. Steffan J., Strehlau G., Maurer M., Rohlfs A. Cyclosporin A pharmacokinetics and efficacy in the treatment of atopic dermatitis in dogs. J. Vet. Pharmacol. Ther. 2004, 27:231-238.
31. Strasser A., Jost P.J., Nagata S. The many roles of FAS receptor signaling in the immune system. Immunity 2009, 30:180-192.
32. Strasser A., Kalmar E., Niedermuller H. A simple method for the simultaneous separation of peripheral blood mononuclear and polymorphonuclear cells in the dog. Vet. Immunol. Immunopathol. 1998, 62:29-35.
33. Takaori K., Nio Y., Inoue K., Tun T., Fukumoto M., Hashida T., Yasuhara M., Hori R., Tobe T. A comparative study on immunosuppressive effects of cyclosporin A and FK 506 on peripheral blood lymphocytes in dogs. Biotherapy 1992, 4:129-137.
34. Tivers M.S., Catchpole B., Gregory S.P., House A.K. Interleukin-2 and interferon-gamma mRNA expression in canine anal furunculosis lesions and the effect of ciclosporin therapy. Vet. Immunol. Immunopathol. 2008, 125:31-36.
35. van den Berg A.P., Twilhaar W.N., van Son W.J., van der Bij W., Klompmaker I.J., Slooff M.J., The T.H., de Leij L.H. Quantification of immunosuppression by flow cytometric measurement of intracellular cytokine synthesis. Transpl. Int. 1998, 11(Suppl. 1):S318-S321.
36. Zucker C., Zucker K., Asthana D., Carreno M., Viciana A.L., Ruiz P., Esquenazi V., Nery J., Burke G., Miller J. Longitudinal induced IL-2 mRNA monitoring in renal transplant patients immunosuppressed with cyclosporine and in unmodified canine renal transplant rejection. Hum. Immunol. 1996, 45:1-12.